Bernard Munos
Non-Executive Director
Bernard Munos is a well-known innovation researcher and the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. He is a senior fellow at FasterCures, a center of the Milken Institute that is dedicated to accelerating biomedical innovation. In the past, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. His research on pharmaceutical innovation has been published in Nature and Science and profiled by Forbes magazine, and he has presented his work globally at leading universities and at meetings sponsored by the President’s Cancer Panel, the National Institutes of Health Leadership Forum, the U.S. Food and Drug Administration, the World Health Organization, the Organization for Economic Cooperation and Development, the New York Academy of Sciences, the Brookings Institution, the Kauffman Foundation, the U.S. Patent and Trademark Office, and the American Chemical Society. He was named one of the 25 most influential people in biopharma by FiercePharma (2012) and previously served on the Advisory Council of the National Center for Advancing Translational Sciences (NCATS) and as a member of the National Academy of Medicine’s Forum on Drug R&D and Translation. In addition, he serves on the Advisory Board of the journal Science Translational Medicine, and as an advisor to or board member of multiple companies and publicly financed research organizations, including Glenmark Pharmaceuticals. He received his master’s degree in business administration from Stanford University and holds other graduate degrees from the University of California at Davis and the Paris Institute of Technology for Life, Food and Environmental Sciences in France.